Creatinine clearance (mL/min) n All-cause mortality (%)

Slides:

Advertisements

Similar presentations

Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.

Advertisements

חזק בהגנה לבבית Valsartan in Heart Failure

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Heart Failure Ben Starnes MD FACC Interventional Cardiology

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Management Strategies for Post-Intervention in Patients with CAD VBWG.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The metabolic syndrome, diabetes, and subclinicalatherosclerosis.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Healthy Lifestyle and Decreasing Risk of Heart Failure.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

Women and Cardiovascular Disease

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

ALBATROSS and REMINDER trials update

Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery S. Venkatesan, P.R. Myles, H.J. Manning,

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

Adjusted mortality risk

The percentage of subjects with de novo development of renal function impairment (GFR

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Mean BP from initial visit to four years

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Prevalence of statin and beta-blocker use by clinical presentation

Figure 2 Three-year survival rates on the basis of body composition

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Volume 93, Issue 4, Pages (April 2018)

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Health ABC: Mortality risk by quintile of cystatin C

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch,

Description of studies for pooled analyses

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome Jonas Faxén, Hong Xu,

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Baseline Characteristics by Baseline N-BNP Level

Patient characteristics: American vs Canadian transplant patients

Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Characteristics of Study Subjects

Nat. Rev. Cardiol. doi: /nrcardio

Absolute mortality difference Change in LVEF from baseline

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

MRRs and EMRRs for women with ACS

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Low/moderate intensity statins High intensity statins

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Increase of physical activity over time associated with lower HF risk

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Adjusted hazard ratio (AHR) of final AVF failure by percent consistent facility aspirin use. Adjusted hazard ratio (AHR) of final AVF failure by percent.

Effect of methylprednisolone versus placebo on the risk of acute kidney injury: subgroup analysis by preoperative chronic kidney disease. Effect of methylprednisolone.

Low/moderate intensity statins High intensity statins

Risk of mortality in patients with diabetes and ESRD

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Role of decreased baroreceptor sensitivity, and activation of RAAS and SNS in expansion of water and sodium retention as well as worsening HF. [Reprinted.

Presentation transcript:

Mortality risk associated with renal insufficiency in women with HF and coronary disease Creatinine clearance (mL/min) n All-cause mortality (%) Adjusted HR* (95% CI) >60 297 13.1 1.0 40-60 283 33.2 1.53 (1.09-2.16) <40 122 53.3 2.40 (1.60-3.62) *Adjusted for demographic features, major comorbidities, and LVEF Bibbins-Domingo K et al. J Am Coll Cardiol 2004; 44:1593-1600.

Mortality risk associated with renal insufficiency in women with HF and coronary disease by ACE inhibitor use Creatinine clearance (mL/min) With ACE inhibitors, adjusted HR* (95% CI) Without ACE inhibitors, adjusted HR* (95% CI) >60 1.0 40-60 0.9 (0.6-1.6) 2.1 (1.3-3.2) <40 1.7 (0.9-3.0) 3.1 (1.8-5.0) *Adjusted for demographic features, major comorbidities, LVEF, and use of beta blockers, aspirin, calcium channel blockers, diuretics, digoxin, and statins Bibbins-Domingo K et al. J Am Coll Cardiol 2004; 44:1593-1600.